COMP360 Psilocybin NDA: FDA Review of Psychedelic Therapy for TRD

COMP360 Psilocybin NDA Submission: A First for Psychedelic Therapies

COMPASS Pathways announced on November 9, 2026, that it has completed its New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for COMP360, a synthetic formulation of psilocybin, for the treatment of treatment-resistant depression (TRD). This marks the first time a psychedelic-based therapy has reached the NDA stage with the FDA, a pivotal regulatory milestone that could reshape the landscape of psychiatric treatment in the United States. The NDA process is a rigorous review that determines whether the therapy can be approved for clinical use based on safety and efficacy data from clinical trials.

Mechanism, Evidence, and Clinical Context

COMP360 is a high-purity, synthetic psilocybin administered in conjunction with psychological support. The NDA submission is supported by data from COMPASS Pathways' Phase 3 clinical program, which included two pivotal trials (NCT05149502 and NCT05144793) enrolling over 900 participants with TRD across multiple countries. These studies evaluated a single 25 mg dose of COMP360, delivered in a controlled setting with trained therapists, compared to placebo and lower-dose arms. The primary endpoint was change in depressive symptoms as measured by the Montgomery–Åsberg Depression Rating Scale (MADRS) at three weeks post-administration.

Results from the Phase 3 program, presented at major psychiatric conferences in 2026, showed a statistically significant reduction in depressive symptoms in the 25 mg group compared to placebo, with some participants achieving sustained response at 12 weeks. However, response rates varied, and not all patients benefited. The therapy is not intended as a first-line treatment but as an option for those who have failed to respond to multiple prior interventions, reflecting the high unmet need in TRD.

Policy, Access, and Precedent-Setting Implications

The FDA's acceptance and review of the COMP360 NDA will set a regulatory precedent for all subsequent psychedelic-based therapies. If approved, COMP360 would be the first psychedelic-assisted therapy available by prescription in the U.S. under federal law. This could influence payer decisions on coverage, the development of clinical infrastructure for psychedelic therapy, and the regulatory approach to other compounds such as MDMA and LSD.

• Insurance Coverage: Approval could prompt insurers to consider reimbursement for psychedelic-assisted therapy, but coverage criteria and cost-effectiveness remain uncertain.
• Clinical Training: The therapy requires specialized therapist training and infrastructure, which may limit initial access and create bottlenecks in care delivery.
• State and Federal Policy: The FDA's decision could inform state-level regulatory reforms, including ongoing efforts in Oregon and Colorado to create legal pathways for supervised psilocybin use outside of clinical trials.

One under-discussed implication is the potential for the FDA to impose Risk Evaluation and Mitigation Strategies (REMS) on COMP360, such as certified provider requirements or patient registries, to manage safety and ensure proper use—an approach previously used for other high-risk psychiatric medications.

Risks, Unknowns, and Failure Modes

While the NDA submission is a milestone, several risks and unknowns remain. The safety profile of COMP360 in clinical trials was generally favorable, but adverse events included transient anxiety, headache, and in rare cases, suicidal ideation. The long-term safety of repeated dosing, off-label use, and use in populations with comorbid psychiatric conditions are not fully characterized.

There is also uncertainty about the scalability and fidelity of psychedelic therapy outside of controlled trial settings. Real-world implementation may face challenges such as therapist shortages, variable adherence to protocols, and potential for misuse. Additionally, the FDA could request further data or impose post-marketing requirements, delaying or limiting access.

Looking Ahead: What Comes Next?

The FDA review process for NDAs typically takes 10-12 months, with a decision expected in late 2027. If approved, COMP360 could become available in specialty clinics under strict protocols, with ongoing monitoring of outcomes and safety. The outcome will shape the trajectory of psychedelic medicine in the U.S., influencing research investment, clinical adoption, and public perception. Researchers and clinicians should prepare for new regulatory guidance and evolving standards of care, while policymakers and payers will need to address questions of access, equity, and oversight.

Author: Dr. Jamie R. Feldman, MD, PhD. Reviewed by Dr. Jamie R. Feldman on 2026-11-10. Research based on FDA, ClinicalTrials.gov, and COMPASS Pathways primary sources.